HCP

ANALYST NOTE: HCP (HashiCorp, Inc.) Date: 2026-06-13 Current Price: $34.78

1. Structural Readiness

State: Context-only Conservative Entry: — Current Price: $34.78 Extension: — ATR at Breakout: — ATR Current: 0.5% (Sub-threshold) Pivot Strength: —

Analysis:

2. Thesis Layer

This is a TACTICAL, setup-led name. There is no named secular thesis or macro theme attached to HCP at this specific date. The investment case must be judged strictly on the quality of the technical setup (the forming coil) and the underlying business fundamentals as recorded by management. No external narrative or sector rotation thesis should be invented to support the position.

3. The Business

Company Profile: HashiCorp, Inc. delivers comprehensive solutions for automating infrastructure across diverse cloud environments globally. The company operates in the software infrastructure automation sector.

Core Offerings:

• Terraform: A key offering embracing an Infrastructure-as-Code (IaC) philosophy for infrastructure provisioning.
• Vault: Dedicated to secrets management and data protection.
• Consul: An application-centric networking automation platform enabling traffic management, security access restriction, and network infrastructure automation.
• Nomad: A workload scheduler and orchestrator providing a self-service interface for overseeing the full application lifecycle.

Business Model & Financials (Management Expectations as of 2024-03-05): Management has outlined a specific recovery trajectory. In the Q1 FY25 earnings transcript (2024-03-05), management stated:

• Revenue Path: "We are on a path back to 20% quarterly revenue growth during FY 2026."
• Recovery Shape: "Our expectation is to see a U-shaped recovery in our revenue growth rates this year, with Q2 being the trough in our revenue growth rates, followed by progressively better revenue growth rates in Q3 and Q4 of this year."
• CRPO Growth: "We expect CRPO growth rates to follow the trough and recovery pattern... ending in approximately 20% CRPO year-over-year growth by the end of fiscal '25."
• Guidance (FY25): For the full fiscal year '25, management expected total revenue in the range of $643 million to $647 million, with a non-GAAP operating loss in the range of $43 million to $46 million.
• Product Strategy: Management introduced long-term support (LTS) releases for commercial customers, enabling customers to stay on a supported version for up to two years with backported critical fixes and security patches.

Financial Spine (as of 2026-06-12): Forward consensus EPS is projected at 0.47742 for FY1 and 0.75667 for FY2.

4. Archetype and Conviction

Archetype: Deep Value Recovery / Margin Inflector The company is positioned as a recovery play following a period of growth deceleration (the "trough" mentioned in 2024 guidance). The introduction of LTS releases and the path to 20% growth by FY26 suggest a structural shift toward recurring revenue stability and margin improvement.

Conviction Stack:

• Thesis Strength: Low (Tactical only; no macro thesis).
• Evidence Quality: Moderate. The 2024 guidance provides a clear roadmap, but the current date (2026) relies on the assumption that the FY25 recovery trajectory was met. The financial spine shows positive EPS growth expectations for FY1 and FY2.
• Structural Quality: The forming coil indicates price stability above support, but the sub-threshold ATR (0.5%) suggests the market is currently in a low-volatility consolidation phase.
• Setup Readiness: Partial. The setup is "forming," meaning the structure is valid, but the breakout trigger has not occurred.
• Rerating Potential: Dependent on the confirmation of the 20% growth trajectory and the successful execution of the LTS strategy.

5. Invalidations, Strengths, and Gaps

What Would Invalidate:

• Management guidance revisions indicating the "U-shaped recovery" has failed or growth rates have decelerated further than the 20% target.

What Would Strengthen:

• A confirmed breakout above the forming coil resistance with expanding volume.
• Confirmation that the FY25 revenue and CRPO growth targets were met, validating the path to FY26 growth.

Gaps in Evidence:

• Current Performance Data: The most recent specific financial data point in the evidence base is from March 2024 (FY25 guidance). There is no specific evidence in the provided block regarding actual results for FY25 or Q1-Q2 FY26 to confirm if the "U-shaped recovery" was successfully executed by the current date of 2026-06-13.
• Volatility Context: The current ATR is sub-threshold, but the "ATR at breakout" is missing, making it difficult to size the potential move relative to historical volatility norms.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key risks: Sub-threshold ATR indicating lack of momentum; Missing evidence of actual FY25/FY26 performance execution; No named secular thesis to support conviction. Sizing hint: Minimal position size due to low volatility and unconfirmed breakout; treat as a watchlist candidate rather than a core holding. Expected path: Price consolidates within the forming coil range; potential for a breakout if volume expands and confirms the recovery thesis; otherwise, continued low-volatility drift. Expected horizon: 3 to 6 months for a potential breakout or invalidation signal.